Abstract
The marked progress in controlling emesis caused by cisplatin characterizes the current status of antiemetic treatment for all chemotherapy. Cisplatin has provided a model for antiemetic studies. Strategies for controlling cisplatin-induced emesis are at least as successful when applied to other chemotherapy, and persistent problems such as delayed emesis and the emesis associated with consecutive-day chemotherapy are also similar to or less severe than those observed with cisplatin. The purpose of this report is twofold: first to outline briefly therapy for cisplatin-induced emesis as illustrated by several new studies, and, second, to report on a new trial that incorporates some different strategies in the control of delayed emesis after cisplatin.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 86-91 |
| Number of pages | 6 |
| Journal | Oncology (Switzerland) |
| Volume | 53 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jan 1 1996 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Cisplatin
- Delayed emesis
- Dexamethasone
- Ondansetron
ASJC Scopus subject areas
- Oncology
- Cancer Research
Fingerprint
Dive into the research topics of 'Cisplatin and Emesis: Aspects of Treatment and a New Trial for Delayed Emesis Using Oral Dexamethasone plus Ondansetron Beginning at 16 Hours after Cisplatin'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS